The discovery of specific molecular aberrations (gene fusions or mutations) has had a profound effect on the understanding and management of myeloproliferative disorders (MPDs). First, it has provided clear evidence that all of these disorders are of neoplastic origin. This fact resulted in the change of the nomenclature proposed in the World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, where the term MPDs was replaced by myeloproliferative neoplasms (MPNs). Second, useful tools for diagnostic procedures were developed, i.e. polymerase chain reaction (PCR) or other molecular assays. Thanks to this, previous complicated diagnostic algorithms could be simplified and the numerical value requirements could be lowered, making the diagnosis simpler and quicker. The other implication of the molecular findings in myeloproliferative neoplasms is derived from the fact that all discovered mutations result in translation of proteins with tyrosine kinase activity. So, nowadays the majority of myeloproliferative neoplasms can be treated with target therapy using tyrosine kinase inhibitors.
proposed more defined criteria. 3 HES was regarded by some authors as a fifth form of MPD.
Originally, Demeshek assumed that these disorders and their different clinical manifestations resulted from the action of undiscovered myelostimulatory factors or mechanisms. Twenty-seven years later,
Adamson and Fialkow postulated that the carcinogenic mutation of multipotential stem cells is the underlying cause of MPD. 4 The discovery of the Philadelphia chromosome (Ph) as a constant cytogenetic aberration in CML, the 6-phospho gluconate dehydrogenase isoenzyme studies in heterozygous females with PV and ET started by Fialkow in 1974 and the clonogenic assay introduced by Bradley and
Metcalf confirmed the hypothesis of the clonal nature of MPDs also in cases of hypereosinophilic syndrome. 5 These factors were manifested in the 2001 edition of the World Health
Organization (WHO) Classification of Tumours of Haematopoietic and
Lymphoid Tissues, in which all of the disorders mentioned above were included in a chapter entitled 'Myeloproliferative Diseases'. 6 At that time the term neoplasm was not used because there was a lack of solid criteria that in every case permitted the distinction of reactive from neoplastic proliferation. This is best illustrated by the fact that in the case of chronic eosinophilic leukaemia (CEL) the term hypereosinophilic syndrome was preserved. Mastocytosis was presented in this classification as a different entity, where cutaneous, usually benign, mastocytosis was put together with systemic forms of the disease.
The development and achievements of molecular biology in the last 25 years have confirmed the concept of the neoplastic nature of these diseases. In almost all of the mentioned disorders, specific molecular markers were found in the form of either gene mutations or gene fusions.
In 1984, the BCR/ABL fusion gene, the result of a translocation between the 9 and 22 chromosomes, in 1993, the KIT gene mutation characteristic of systemic mastocytosis and in 2003, the FLIP1L1/ PDGFRA fusion gene characteristic for CEL were described. 7, 8, 9 Two years later, the JAK2 gene mutation, found in the majority of PV cases and at least half of ET and MF cases, was uncovered. [10] [11] [12] All of the mentioned mutations result in translation of proteins with tyrosine kinase activity. They are responsible for constitutive activations of molecular pathways, leading to uncontrolled cell proliferation in MPDs. So, although these mutations have proved the neoplastic origin of MPDs, in some ways they are in accordance with Dameshek's concept of dysregulation of myelopoesis. 18 or additional molecular events. 19, 20 In the new WHO classification, CEL is included in the MPNs, but only as the entity without molecular marker (not otherwise specified
[NOS]). In our opinion, it was not advisable to drop the well-defined Haematological Malignancies Although initial enthusiasm was dampened by long-term observation, nothing can deny the fact that oral, patient-friendly and low-intensity adverse-effect-causing therapy improved the life expectancy of CML patients, even compared with bone marrow transplantation. This conclusion was the basis for profound changes in standard therapy to imatinib as a first-line treatment in nearly all patients. However, long-term observations revealed that molecular remission is not obtained in 20-30% of patients even after 60 months of treatment, and it is lost in time by some patients.
The patients having no benefits of target therapy with imatinib became a group of special interest for clinical studies with imatinib.
Long-term observations showed that the time to the consecutive phase of response varies among patients. This finding resulted in optimisation of the treatment time needed to achieve the next phase of clinical response. 22 The studies in the group of patients with late molecular response as well as in those who lost molecular response created the necessity for defining laboratory methods and therapy-monitoring standards. in ligand-independent activation of KIT kinase and provides resistance to imatinib. 25 In these cases, dastinib appeared to be an effective drug. 26 However, activating point mutations in other codons of the KIT gene may be sensitive to imatinib. In our unpublished data, we have evidence of achieving a good response in patients with SM and codon 502-503 duplication of the the KIT gene mutation, which was previously described in patients with gastrointestinal stromal tumours (GIST). 27 Low doses of imatinib could also be used in patients with CEL and FIP1L1-PDGFRA mutation with excellent therapeutic effects, 28 even compared with results of bone marrow transplantation. The risk of complications in PV and ET was studied by some authors. Thrombotic history and age >60 years in both PV and ET seem to be incontestable factors. The importance of cardiovascular risk factors is still unclear. The latest reports show that leukocytosis can be regarded as a risk factor for complications as well as blast transformation. 31 The recognition of these risk factors needs further study; moreover, the platelet count seems not to be prognostic. The high risk of bleeding in patients with extremely high platelet counts (>1,000G/l) is currently regarded as a phenomenon related to acquired von Willebrand disease. 32 The presence of any known risk factors classifies the patient into the high-risk group.
In the case of PV, patients usually undego phlebotomies and are put on low-dose aspirin. When patients are in the high-risk group, therapy with hydroxyurea (HU) is started. When intolerance or resistance to HU occurs, it is permitted to use interferon-α, pipobroman or myleran as a second-line therapy.
Myeloproliferative Neoplasms Considering the developments in molecular biology in the few last years and recent proteomics studies, one could also expect that in the near future a specific molecular marker will be found for all patients with a diagnosis of myeloproliferative neoplasms, and the 
